To our knowledge, this is the first study to show that higher level of HER2 amplification by ISH is associated with favorable treatment outcomes in patients with advanced HER2-positive breast cancer treated with first-line pertuzumab, trastuzumab, and docetaxel. The gene discussed is ERBB2; the disease is breast carcinoma.